Surmodics’ (SRDX) Hold Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their hold rating on shares of Surmodics (NASDAQ:SRDX) in a research report released on Monday morning, Benzinga reports.

SRDX has been the subject of a number of other research reports. StockNews.com began coverage on Surmodics in a research note on Saturday, August 3rd. They issued a hold rating for the company. Barrington Research reiterated a market perform rating on shares of Surmodics in a research report on Thursday, May 30th. Sidoti restated a neutral rating and set a $43.00 target price on shares of Surmodics in a research report on Wednesday, May 29th. Finally, Lake Street Capital reissued a hold rating and set a $43.00 price objective on shares of Surmodics in a report on Wednesday, May 29th. Five equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company presently has an average rating of Hold and a consensus price target of $50.00.

Surmodics Trading Up 0.1 %

Shares of Surmodics stock opened at $41.11 on Monday. Surmodics has a fifty-two week low of $25.17 and a fifty-two week high of $42.44. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.59 and a current ratio of 3.98. The company has a market capitalization of $586.64 million, a P/E ratio of 43.27 and a beta of 1.18. The company has a fifty day moving average of $41.82 and a 200 day moving average of $34.71.

Institutional Investors Weigh In On Surmodics

Several large investors have recently added to or reduced their stakes in SRDX. SG Americas Securities LLC boosted its holdings in shares of Surmodics by 14.7% in the 1st quarter. SG Americas Securities LLC now owns 5,138 shares of the company’s stock worth $151,000 after purchasing an additional 660 shares during the period. Hillsdale Investment Management Inc. grew its holdings in Surmodics by 15.7% during the 4th quarter. Hillsdale Investment Management Inc. now owns 4,570 shares of the company’s stock valued at $166,000 after purchasing an additional 620 shares during the last quarter. Lazard Asset Management LLC raised its position in Surmodics by 13.4% in the 1st quarter. Lazard Asset Management LLC now owns 5,679 shares of the company’s stock worth $166,000 after purchasing an additional 673 shares during the period. BNP Paribas Financial Markets lifted its stake in Surmodics by 7.5% in the first quarter. BNP Paribas Financial Markets now owns 6,878 shares of the company’s stock worth $202,000 after purchasing an additional 481 shares during the last quarter. Finally, Hardin Capital Partners LLC purchased a new position in shares of Surmodics during the second quarter valued at approximately $206,000. 96.63% of the stock is owned by institutional investors.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).